IO Biotech, Inc. — fact timeline

IO Biotech, Inc. faced acceleration on loan of €22.5 million with European Investment Bank.

“The appointment of the Chapter 7 trustee as described in Item 1.03 of this Current Report on Form 8-K triggers an event of default under the finance contract between the Company’ subsidiary IO Biotech ApS and the European Investment Bank (“EIB”) and provides EIB the right to terminate the finance contract and demand from the Company and IO Biotech ApS immediate repayment of the €22.5 million drawn under the finance contract together with accrued interest, prepayment fees and certain costs and expenses.”

IO Biotech, Inc. entered chapter 7 in United States Bankruptcy Court for the District of Delaware (petition 2026-03-31).

“On March 31, 2026, after considering all strategic alternatives, IO Biotech, Inc. (the “Company”) ceased operations and filed a voluntary petition for relief (the “Petition”) under the provisions of Chapter 7 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).”

IO Biotech, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“February 12, 2026, IO Biotech, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the continued listing requirements for The Nasdaq Global Select Market because the market value of the Company’s listed securities (“MVLS”) was below the minimum of $50 million for a period of 30 consecutive business days, as required by Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Gl”

IO Biotech, Inc. announced a restructuring with charges of approximately $2.4 million to $2.6 million affecting globally.

“As part of previously announced efforts by IO Biotech, Inc. (the “Company”) to reduce the Company’s operating expenses while the Company explores a range of strategic alternatives, the Board of Directors of the Company approved on January 21, 2026, a restructuring and workforce reduction plan (the “Plan”) which is expected to result in a significant reduction of the Company’s workforce globally. In connection with the implementation of the Plan, the Company expects to incur one-time charges and cash expenditures in a range of approximately $2.4 million to $2.6 million, primarily related to employee wages and severance payments, healthcare continuation, earned vacation time and related termination costs.”

IO Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 17, 2025, IO Biotech, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, and the Company’s commo”

IO Biotech, Inc. announced a restructuring with charges of approximately $1.0 million to $1.5 million (approximately 50% of the Company’s workforce globally).

“On September 25, 2025, the Board of Directors of IO Biotech, Inc. (the “Company”) approved a restructuring and workforce reduction plan (the “Plan”) to conserve capital to align the Company’s operations with its primary focus of advancing development of Cylembio ® (imsapepimut and etimupepimut, adjuvanted). The Plan is expected to result in a reduction of approximately 50% of the Company’s workforce globally. In connection with the implementation of the Plan, the Company expects to incur one-time charges and cash expenditures in a range of approximately $1.0 million to $1.5 million, primarily related to employee wages and severance payments, healthcare continuation, earned vacation time and related termination costs.”

IO Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 26, 2024, IO Biotech, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, and the Company’s commo”

IO Biotech, Inc.: Adopted amended and restated bylaws with revisions to stockholder nomination mechanics, Rule 14a-19 compliance, meeting procedures, DGCL conformity, and ministerial changes (effective 2024-12-13).

“On December 13, 2024, the board of directors (the “Board”) of IO Biotech, Inc. (the “Company”) adopted amended and restated bylaws of the Company (the bylaws, as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.”

IO Biotech, Inc. reported the first quarter ended March 31, 2024 results: net income $19.5 million.

“Net loss for the three months ended March 31, 2024, was $19.5 million”

Jack Nielsen resigned as Member of the Board of Directors at IO Biotech, Inc..

“On April 24, 2024, Jack Nielsen, a member of the board of directors (the “Board”) of IO Biotech, Inc. (the “Company”), notified the Company of his resignation from the Board, effective that same date.”

IO Biotech, Inc. reported three months ended December 31, 2023 results: net income $26.2 million.

“Net loss for the three months ended December 31, 2023, was $26.2 million, compared to $20.1 million for the three months ended December 31, 2022.”

IO Biotech, Inc. reported the quarter ended September 30, 2023 results: net income $21.7 million.

“Net loss for the three months ended September 30, 2023, was $21.7 million, compared to $15.7 million for the three months ended September 30, 2022.”

Helen Collins was appointed as Class II Director at IO Biotech, Inc..

“On November 9, 2023, the Company increased the size of the Board from seven to eight directors, and appointed Helen Collins, M.D. as a Class II director of the Company to fill the vacancy, effective as of that same date.”

IO Biotech, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $21.2 million.

“Net loss for the three months ended June 30, 2023 was $21.2 million”

Priyanka Belawat resigned as Director at IO Biotech, Inc..

“On August 7, 2023, Priyanka Belawat, a member of the Board of Directors of the Company, notified the Company of her resignation from the Board, effective that same date.”

Heidi Hunter was appointed as Class II director at IO Biotech, Inc..

“On August 8, 2023, the Company appointed Heidi Hunter as a Class II director of the Company, effective as of August 11, 2023.”

IO Biotech, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2023-08-07).

“On August 7, 2023, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers.”

IO Biotech, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $75.1 million (effective 2023-08-07).

“On August 7, 2023, IO Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue (i) 37,065,647 shares of the Company’s common stock (“Common Stock”), and (ii) 37,065,647 warrants to purchase up to 37,065,647 shares of Common Stock (the “Warrants”) in a private placement transaction (the “Private Placement”).”

Eva Ehrnrooth changed role as Senior Clinical Advisor at IO Biotech, Inc..

“Dr. Ehrnrooth will now transition from her role as Chief Medical Officer to Senior Clinical Advisor, effective immediately.”

Qasim Ahmad was appointed as Chief Medical Officer at IO Biotech, Inc..

“On July 15, 2023, IO Biotech, Inc. (the “Company”) appointed Qasim Ahmad, M.D. as the Company’s Chief Medical Officer, effective as of that same date.”

IO Biotech, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.

“Proposal Three: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote: For Against Abstain Broker Non-Votes 20,815,596 111,302 4,683 —”

IO Biotech, Inc. shareholders approved Amendment to the Certificate of Incorporation to Provide Exculpation for Officers at the 2023-06-08 meeting.

“Proposal Two: Amendment to the Certificate of Incorporation to Provide Exculpation for Officers The stockholders approved an amendment to the Company’s Certificate of Incorporation to provide exculpation for officers by the following vote: For Against Abstain Broker Non-Votes 20,021,960 115,161 4,875 789,675”

IO Biotech, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.

“Proposal One: Election of Class II Directors Each of Priyanka Belawat and Christian Elling was elected to serve as a class II director to hold office until the Company’s 2026 Annual Meeting of Stockholders and until the election and qualification of his or her successor. Votes were cast as follows: For Withheld Broker Non-Votes Priyanka Belawat, Ph.D. 18,148,150 1,993,756 789,675 Christian Elling, Ph.D. 18,139,833 2,002,073 789,675”

IO Biotech, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $17.0 million.

“Net loss for the three months ended March 31, 2023 was $17.0 million, compared to $17.2 million for the three months ended March 31, 2022.”

Vanessa Malier resigned as member of the board of directors at IO Biotech, Inc..

“On April 17, 2023, Vanessa Malier, a member of the board of directors (the “Board”) of IO Biotech, Inc. (the “Company”), notified the Company of her resignation from the Board, effective that same date.”

IO Biotech, Inc. reported the year ended December 31, 2022 results: net income $71.5 million.

“Net loss for the year ended December 31, 2022, was $71.5 million”

IO Biotech, Inc. reported third quarter ended September 30, 2022 results: net income $15.7 million.

“IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today financial results for the quarter ending September 30, 2022.”

Amy Sullivan was appointed as Chief Financial Officer at IO Biotech, Inc..

“On October 13, 2022, IO Biotech, Inc. (the “Company”) appointed Amy Sullivan, 53, as the Company’s Chief Financial Officer, effective as of October 15, 2022.”

Brian Burkavage was appointed as Chief Accounting Officer at IO Biotech, Inc..

“On May 12, 2022, the Company appointed Brian Burkavage, 39, the Company’s Vice President of Finance, as its Chief Accounting Officer, effective immediately.”

Keith Vendola was terminated as Chief Financial Officer at IO Biotech, Inc..

“On May 9, 2022, IO Biotech, Inc. (the “Company”) and Keith Vendola, Chief Financial Officer of the Company, have terminated Mr. Vendola’s employment with the Company by mutual agreement, effective immediately.”

Emmanuelle Coutanceau departed as Director at IO Biotech, Inc..

“On the same date, Dr. Emmanuelle Coutanceau, a director of the Board, notified the Company that she will not stand for reelection at the Company’s 2022 annual meeting of stockholders.”

Claus Andersson departed as Director at IO Biotech, Inc..

“On April 12, 2022, Dr. Claus Andersson, a director of the board of directors (the “Board”) of the IO Biotech, Inc. (the “Company”), notified the Company that he will not stand for reelection at the Company’s 2022 annual meeting of stockholders.”

David V. Smith was appointed as Director at IO Biotech, Inc..

“On February 28, 2022, the Board of Directors of IO Biotech, Inc. (the “Company”) appointed David V. Smith as a director of the Company, effective as of March 1, 2022.”